GU Cancers 2025 | Gut microbiota as a biomarker for pembrolizumab response in UC
Soufyan Annakib
• 14 Feb 2025
Soufyan Annakib, MD, Centre Hospitalier Universitaire de Nîmes, Nîmes, France, discusses a prospective multicenter study investigating the gut microbiome as a potential biomarker for pembrolizumab efficacy in advanced urothelial carcinoma (UC). Fecal metaproteome analysis revealed differences in taxonomic and functional composition between responders and non-responders. Specific bacterial genera, such as Sutterella were also associated with treatment response. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
